Navigation Links
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Date:10/22/2007

- Company Plans to Move Compound Forward into Phase III -

- Conference Call Scheduled for Today at 9:00 A.M., Eastern Time -

LA JOLLA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that tezampanel met the primary endpoint in a 306-patient, Phase IIb clinical trial for the treatment of a single, acute migraine attack. In the study, which evaluated tezampanel administered subcutaneously, the 40 mg dose demonstrated statistically significant improvement on headache pain response at two hours post-dose compared to placebo (78.2 percent versus 58.7 percent; p=0.033, corrected for multiplicity) and the response was sustained through 24 hours post-dose. Although not powered to demonstrate statistical significance, improvement in key secondary measures at 40 mg, nevertheless, were either statistically significant (p<0.050) or trending (p<0.100) when compared to placebo and corroborated the results for the primary endpoint of the study. These key secondary measures included nausea or vomiting, photophobia, a sum of pain intensity scores at three and four hours post-dose, sustained headache response at 24 hours, functional disability and a composite score of core migraine symptoms at two and four hours post-dose that included measures of headache severity, nausea, vomiting, photophobia, phonophobia and functional disability. Two other doses of tezampanel, 70 mg and 100 mg, were evaluated and also demonstrated effects across various pain measures although neither dose reached statistical significance on the primary endpoint. The company intends to submit the data from this trial to the U. S. Food and Drug Administration (FDA) in order to initiate a Phas
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)
10. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
11. Replidyne Phase II Pediatric Trial Meets Primary Objective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece published ... side of plastic surgery and explained why people should not shy away from their ... the excesses of the few and celebrate it for the modern wonder that it ...
(Date:7/27/2015)... ... 2015 , ... The Maricopa Community Colleges today announced a new ... to get into and complete college. , The “Bridging Success Initiative,” funded by ... with partners from across the valley. , The initiative advisory board has representatives from ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ... hiking to its options. Already an industry leader because of its use ... lookout for the latest successful trends in helping people to overcome addiction and ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they ... that tooth loss can incur a lot of stress, pain, discomfort and embarrassment, which ... The All-On-4™ treatment reaps the benefits of implants with the cost savings of ...
(Date:7/27/2015)... ... 2015 , ... Hexagon Geospatial is pleased to introduce the ... your geospatial experience. These new light-weight applications cohesively combine data, workflows, and analytics. ... “Our world is more dynamic than it has ever been,” said Mladen Stojic, ...
Breaking Medicine News(10 mins):Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 2Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 3
... The schools in the US appear to be suffering from ... single nurse only. There are about 56,000 nurses working across ... to one nurse for every 950 students, while the federal ... nurse to student ratio is the worst in Utah, when ...
... acquitted on Wednesday of murdering three of his patients with ... a retired army officer from North Wales, was found not ... of three seriously ill men, after a six-week trial. No ... the deaths of other patients under the care of Dr ...
... The vice president of Sandia National Laboratories, Gerry Yonas was the ... ,This led to the development of the BiNational Sustainability ... at Santa Teresa. This will mainly augment the border security ... Canada & Mexico. ,The monetary inputs for ...
... community medicine and colleagues developed the latest tool for identifying ... tool which is called the Newest vital sign. It is ... an ice cream nutrition label. Based on the number of ... be calculated. , Then it is for the ...
... gobbi and his team from Universite de Montreal ... the level of endocannabinoids by blocking the degradation ... chemicals present in brain which is responsible for ... receptors are triggered during exercises and other well-being ...
... the Annals of Internal Medicine this week have found ... the verge of kidney failure is useless. //The study ... in London, Canada found that a treatment called "plasma ... ,This means that the money which is ...
Cached Medicine News:Health News:School Children Put To Risk Due To Shortage Of Nurses 2Health News:British Doctor cleared of murder 2
... is a collarless flat wedge-shaped implant ... in a design that is relatively ... incorporation of standard and lateralized offset ... to reconstruct a stable joint with ...
Build your Basic Small Joint Set from the suggested instruments or select other insruments for the set....
Supplemental instrument to the Small Joint Arthroplasty System....
... The HUNTER Active & Passive Tendon ... one or the two-stage procedure developed by ... of flexor and extensor tendons in individuals ... intended to be implanted temporarily in order ...
Medicine Products: